Endoglin/CD105 Antibody [ADC] - (Carotuximab Vedotin, Research Grade)

Immobilized human CD105 His at 2 ug/mL can bind Endoglin/CD105 (Carotuximab Vedotin) Antibody, EC50=0.2864 ug/mL.

• Reactivity: Hu
• Applications: ELISA, Flow, Func
• Clonality: Monoclonal
• Host: Human
• Conjugate: ADC
• Concentration: LYOPH

Endoglin/CD105 Antibody [ADC] - (Carotuximab Vedotin, Research Grade) Summary

• Description: This product is an Antibody-Drug Conjugate (ADC) for Research Use Only (RUO).
  
  Carotuximab-MMAE is an ADC consisting of a CD105-directed antibody and Monomethyl auristatin E (MMAE) that exhibits antitumor activity.
  
  This product is shipped at ambient temperature. Upon receipt, store immediately at -20C or lower for 12 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
• Immunogen: Endoglin/CD105 (Uniprot: P17813)
• Source: CHO
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Human
• Purity: > 90% by SDS-PAGE and HPLC

Applications/Dilutions

• Dilutions:
  • ELISA
  • Flow Cytometry
  • Functional
• Theoretical MW: 145 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at -20C in powder form. Store at -80C once reconstituted.
• Buffer: Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
• Preservative: No Preservative
• Concentration: LYOPH
• Purity: > 90% by SDS-PAGE and HPLC
• Reconstitution Instructions: Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

Alternate Names for Endoglin/CD105 Antibody [ADC] - (Carotuximab Vedotin, Research Grade)

• CD105 antigen
• CD105
• Endoglin
• ENDOsler-Rendu-Weber syndrome 1
• ENG
• HHT1FLJ41744
• ORW
• ORW1

Background

CD105 is a 90 kD homodimeric type I integral membrane glycoprotein, also known as endoglin. It is expressed on endothelial cells (especially on angiogenic endothelial cells) and up-regulated by hypoxia, activated monocytes, macrophages, bone marrow stromal cells, and some cytotrophoblasts. CD105 is a receptor for TGF- szlig1, TGF- szlig3 and modulates TGF- szlig signaling by interacting with TGF- szlig receptors I and/or II. CD105 also binds other growth factors such as actvin A, BMP-2 and -7. CD105 has been show to be a useful marker for identifying proliferating endothelium involved in tumor angiogenesis and can be used for tumor imaging, prognosis, as well as has therapeutic potential for some solid tumors and other angiogenic diseases.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

FAQs for Endoglin/CD105 (Carotuximab Vedotin) Antibody (NBP3-44525). (Showing 1 - 2 of 2 FAQ).

1. I wonder if you have a CD105 or CD34 antibody suitable for IHC that is specific for human and do not bind mouse?
   • We do not have any anti-human CD34 or CD105 antibodies that are confirmed to NOT detect the mouse protein. When we have tested an antibody and confirmed that it will not react with mouse samples, we will add Mu(-) to the datasheet, and unfortunately all of our CD105 and CD34 antibodies will either detect the mouse protein, or they have not been used in mouse samples before.
2. We are interested in CD105 antibodies that could react with dog, please let me know which products in your catalog you would recommend.
   • We do not currently carry any CD105 antibodies that have been validated for use in dog samples. However, if you are interested in testing any of our CD105 antibodies with dog samples you would be eligible for our Innovators Reward Program, in which you can get a discount voucher for the purchase price of the product. Please contact us at innovators@novusbio.com with any questions regarding this program.